Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1990 Mar;73(2):113-23.

[Radiotherapy and ovarian carcinoma. Experience in 139 patients]

[Article in Dutch]
Affiliations
  • PMID: 2195005
Review

[Radiotherapy and ovarian carcinoma. Experience in 139 patients]

[Article in Dutch]
P Huget et al. J Belge Radiol. 1990 Mar.

Abstract

Between 1969 and the end of 1984, 104 patients with stage I to III ovarian carcinoma were referred for treatment. All patients had surgery before referral. There were 42 stage I, 32 stage II and 30 stage III patients. In one third of the patients the previous surgery was incomplete. Another 35 patients with advanced (stage IV) ovarian carcinoma or with an abdomino-pelvic recurrence after surgery were referred for palliative treatment. Distribution of the patients according to age, stage and histologic type was not different from the series reported in the literature. Radiation therapy was given over the pelvis up to 45 Gy midline dose. A lumbo-aortic field, 25 Gy up to the diaphragm, was added for stage III patients. Five year survival after complete surgery was respectively 80.5%, 65.5% and 33.3% for stage I, II and III. After incomplete surgery the data dropped to 70%, 33% and 6.6%. Overall five year survival is nevertheless 57.6%. These results are compared to similar published series (surgery and radiotherapy). The outcome is very similar. Adjuvant radiation therapy in adequate dose over the pelvis is worthwhile for ovarian carcinoma stage I-II, and with lumbo-aortic irradiation for stage III, providing surgery was aggressive.

PubMed Disclaimer

Similar articles

LinkOut - more resources